CLARISCAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Clariscan, and when can generic versions of Clariscan launch?
Clariscan is a drug marketed by Ge Healthcare and is included in one NDA.
The generic ingredient in CLARISCAN is gadoterate meglumine. Four suppliers are listed for this compound. Additional details are available on the gadoterate meglumine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Clariscan
A generic version of CLARISCAN was approved as gadoterate meglumine by HENGRUI PHARMA on April 11th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CLARISCAN?
- What are the global sales for CLARISCAN?
- What is Average Wholesale Price for CLARISCAN?
Summary for CLARISCAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Drug Prices: | Drug price information for CLARISCAN |
| DailyMed Link: | CLARISCAN at DailyMed |
Pharmacology for CLARISCAN
| Drug Class | Gadolinium-based Contrast Agent |
| Mechanism of Action | Magnetic Resonance Contrast Activity |
US Patents and Regulatory Information for CLARISCAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | CLARISCAN | gadoterate meglumine | SOLUTION;INTRAVENOUS | 210016-005 | Nov 24, 2020 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Ge Healthcare | CLARISCAN | gadoterate meglumine | SOLUTION;INTRAVENOUS | 210016-003 | Nov 1, 2019 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Ge Healthcare | CLARISCAN | gadoterate meglumine | SOLUTION;INTRAVENOUS | 210016-001 | Nov 1, 2019 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
